



HAL
open science

Smoking history and cognitive function in middle age from the Whitehall II study.

Séverine Sabia, Michael G. Marmot, Carole Dufouil, Archana Singh-Manoux

► **To cite this version:**

Séverine Sabia, Michael G. Marmot, Carole Dufouil, Archana Singh-Manoux. Smoking history and cognitive function in middle age from the Whitehall II study.. Archives of Internal Medicine, 2008, 168 (11), pp.1165-73. 10.1001/archinte.168.11.1165 . inserm-00291578

HAL Id: inserm-00291578

<https://inserm.hal.science/inserm-00291578>

Submitted on 9 Jun 2009

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Title: Smoking history and cognitive function in middle-age: the Whitehall II study

Séverine Sabia, MSc^{1*}

Michael Marmot, PhD, FFPHM, FRCP²

Carole Dufouil, PhD³

Archana Singh-Manoux, PhD^{1,2,4}

*Corresponding author, author to receive reprint requests & address

¹INSERM U687-IFR69

Hopital Paul Brousse,

16 avenue Paul Vaillant Couturier, Bâtiment 15/16,

94807 Villejuif Cedex

Tel: + 33 (0)1 77 74 74 00; Fax: + 33 (0)1 77 74 74 03

Email: Severine.Sabia@st-maurice.inserm.fr

²Department of Epidemiology and Public Health, University College London, UK

³INSERM U708, Paris, France; Université Paris6, Paris, France

⁴Centre de Gérontologie, Hôpital Ste Perine, AP-HP

Financial support: AS-M is supported by a “Chaire d’excellence” award from the French Ministry of Research and a “European Young Investigator Award” from the European Science Foundation. MM is supported by an MRC research professorship. The Whitehall II study has been supported by grants from the British Medical Research Council (MRC); the British Heart Foundation; the British Health and Safety Executive; the British Department of Health; the National Heart, Lung, and Blood Institute (grant HL36310); the National Institute on Aging (grant AG13196); the Agency for Health Care Policy and Research (grant S06516); and the John D. and Catherine T. MacArthur Foundation Research Networks on Successful Midlife Development and Socioeconomic Status and Health.

Conflict of interest: none

Word count manuscript: 3460; abstract: 250

Abstract

Background: Studies on the association between smoking and dementia are necessarily on those who have “survived” smoking. We examined the association between smoking and cognition in middle-age and estimate the risk of death and non-participation among smokers.

Methods: Data come from the Whitehall II study of 10308 participants, aged 35–55 years at baseline (phase 1; 1985-1988). Smoking history was assessed at Phases 1 and 5 (1997-1999). Cognitive data (memory, reasoning (AH4-I), vocabulary, semantic and phonemic fluency) were available on 5,346 participants at Phase 5, 4,630 of these were retested 5-years later.

Results: Smokers at Phase 1 were at higher risk of death (Hazard Ratio (HR), 2.00 (95% Confidence Interval (CI), 1.58-2.52) in men, and HR, 2.46 (1.80-3.37) in women) and non-participation in cognitive tests (Odds Ratio (OR), 1.32 (1.16-1.51) in men, OR, 1.69 (1.41- 2.02) in women). At Phase 5, in age- and sex-adjusted analyses, smokers compared to “never smokers” were more likely to be in the lowest quintile of cognitive performance. After adjustment for multiple covariates, this risk remained for memory (OR, 1.37 (1.10-1.73)). Ex-smokers at Phase 1 had 30% lower risk of poor vocabulary and verbal fluency. In longitudinal analysis, the evidence for an association between smoking history and cognitive decline was not consistent. Finally, stopping smoking during the follow-up was associated with improvement in other health behaviours.

Conclusions: Smoking was associated with greater risk of poor memory. The loss to follow-up was significant among smokers. Ex-smokers had lower risk of poor cognition, possibly due to improvement in other health behaviours.

The association between smoking and dementia has been much discussed in recent years¹⁻³ with a recent meta-analysis concluding that smoking is a risk factor for dementia⁴. This association is thought to be primarily through the effect of smoking on vascular disease^{2, 4}. Examining this effect in the elderly is problematic due to loss during follow-up, misdiagnosis of dementia, and smoking related premature mortality before the onset of dementia^{2, 3}. In order to avoid some of these problems, one approach entails exploring the association between smoking and cognition before the onset of dementia. There is increasing evidence to suggest the importance of midlife risk factors for later dementia⁵. Furthermore, the link between cognitive impairment and later life dementia⁶⁻⁸ is clearly established. Thus, it is important to examine if the risk of cognitive impairment in smokers is also present in midlife⁹⁻¹⁵; evidence of this association at younger ages would support the hypothesis that smoking is involved in the pathogenesis of preclinical cognitive deficit and decline.

We aim to investigate the association between history of tobacco consumption (smoking status, pack-years of smoking) and multiple domains of cognition in middle-aged individuals. We examine associations with cognitive performance and change in cognitive function over a five-year period in analysis adjusted for the effects of socioeconomic status, health behaviours and a range of health indicators. A further objective was to assess the extent to which even middle-aged smokers are lost to follow-up, either through death or through non-participation.

METHODS

Data are drawn from the Whitehall II study, established in 1985 to examine the socioeconomic gradient in health and disease among 10,308 civil servants (6,895 men and 3,413 women)¹⁶. All civil servants aged 35-55 years in 20 London based departments were invited to participate by letter, and 73 percent agreed. Baseline examination (Phase 1) took place during 1985-1988, and involved a clinical examination and a self-administered questionnaire containing sections on demographic characteristics, health, lifestyle factors as smoking habits, work

characteristics, social support and life events. Clinical examination included measures of blood pressure, anthropometry, biochemical measurements, neuroendocrine function, and subclinical markers of cardiovascular disease. Subsequent phases of data collection have alternated between postal questionnaire alone (Phases 2 (1988-1990), 4 (1995-1996), 6 (2001) and 8 (2006)) and postal questionnaire accompanied by a clinical examination (Phases 3 (1991-1994), 5 (1997-1999) and 7 (2002-2004)). Participants gave written consent to participate in the study and the University College London ethics committee approved the study.

Smoking History

Data on smoking were collected at every phase using questions on smoking status (current, past, never), age at which the participant started smoking, average number of cigarettes per day, number of cigars/cigarillos smoked, ounces of tobacco smoked in a pipe or in hand-rolled cigarettes per week (see figure 1). Ex-smokers were asked the age at which they had stopped smoking. The smoking history variable was created with the following categories: “current smoker at Phase 5”, “recent ex-smoker” (stopped smoking between Phases 1 and 5), “long-term ex-smoker” (those who stopped before Phase 1) and “never smoker”. Among “smokers” at Phase 5, we further used the amount of tobacco smoked, in total grams of tobacco per day (one cigarette=1 g, one cigar/cigarillos=3 g)¹⁷, to calculate pack-years of smoking (average daily number of grams of tobacco divided by 20 and multiplied by the number of years of smoking).

Cognition

Cognitive function was assessed at Phases 5 and 7 using a battery of five standard tasks, described below.

Short-term verbal memory was assessed with a 20-word free recall test. Participants were presented a list of 20 one or two syllable words at two second intervals and were then asked to recall in writing as many of the words in any order and had two minutes to do so.

The AH4-I (Alice Heim 4-I) is composed of a series of 65 verbal and mathematical reasoning items of increasing difficulty¹⁸. It tests inductive *reasoning*, measuring the ability to identify patterns and infer principles and rules. Participants had 10 minutes to do this section.

Vocabulary was assessed using the *Mill Hill Vocabulary test*¹⁹, used in its multiple format, consisting of a list of 33 stimulus words ordered by increasing difficulty and six response choices.

We used two measures of *verbal fluency*: phonemic and semantic²⁰. Phonemic fluency was assessed via “S” words and semantic fluency via “animal” words. Subjects were asked to recall in writing as many words beginning with “s” and as many animal names as they could. One minute was allowed for each test.

Covariates

Socio-demographic variables used were age, sex, socioeconomic position (using the British civil service grade of employment - high (administrative), intermediate (professional or executive) and low (clerical or support) grades), education (no or lower primary school, lower secondary school, higher secondary school, university, and higher university degree) and marital status (married/cohabiting, single, widowed, and divorced/separated).

Health behaviours were as follows. Alcohol consumption, assessed via questions on the number of alcoholic drinks (“measures” of spirits, “glasses” of wine, and “pints” of beer) consumed in the last seven days, converted to number of units of alcohol. Frequency of fruit and vegetable consumption, assessed using the question “How often do you eat fresh fruit or vegetables?”; responses were on an eight-point scale, ranging from ‘seldom or never’ to ‘two or more times a day’. Physical activity, calculated as the sum of the hours of mild, moderate, and vigorous physical activities in response to a 20-item questionnaire on the frequency and duration of participation in walking, cycling, sports, gardening, housework, and home maintenance²¹.

Health measures were drawn from Phase 5. Coronary heart disease prevalence was based on clinically verified events and included myocardial infarction and definite angina²². Stroke and

diabetes were assessed using self-reports of doctor diagnosis. Blood pressure, systolic and diastolic, was measured at the Phase 5 clinical examination, twice in the sitting position after five minutes rest with an automated Omron 907 device. The average of two measures was taken to be the measured blood pressure. Serum cholesterol was measured within 72 h in serum stored at 4°C using enzymatic colorimetric methods.

Statistical methods

The association between smoking status at Phase 1 (never smoker, ex-smoker and current smoker) and mortality till Phase 7 was assessed using Cox regression and that with non-participation in cognitive tests at Phase 7 using logistic regression.

Descriptive analyses as a function of smoking history at Phase 5 were carried out and tested using chi-square analysis for trend for categorical variables and by fitting a linear trend for continuous variables. We first assessed the association between smoking history and continuous measures of cognition using linear mixed-effects models to account for unequal time interval between the two clinical examinations, between 3.9 and 7.1 years. The independent variables were smoking history, time, interaction term between smoking history and time since first cognitive assessment, and other covariates. The dependent variables were the cognitive measures. Next, we examined the association between smoking history and the dichotomised measures of cognition in logistic regression, where the reference group was the “never smoker” category. Cognitive scores in the lowest sex-specific quintile were seen to represent cognitive deficit at Phase 5 and those in the worst sex-specific quintile of change to represent decline. The time interval between the two measures of cognition has been adjusted for in the analyses of change using logistic regression. The analyses were adjusted first for age and sex, then for socio-demographic measures (education and age as continuous, all others as categorical), and finally for health behaviours (all continuous) and health measures (all vascular risk factors as continuous).

Other ways of looking at smoking history (age of starting smoking, time since stopping smoking, etc.) were also examined in exploratory analysis but are not presented here, except for analysis using “pack-years” of smoking for current smokers, as the results are not strikingly different. In addition, we undertook post-hoc analysis to examine changes in health behaviours (consumption of alcohol and of fruits and vegetable) between Phases 1 and 7 in the four smoking history categories. All analyses were performed using SAS statistical software, version 8.

RESULTS

Sample description and missing data

Of the 10,308 participants at Phase 1 (1985–1988), 7,830 participated in at least one part of Phase 5 (1997–1999), 2,204 were non responders and 274 dead (figure 1). At Phase 5, data on cognitive function, smoking history and all covariates were available for 5,388 respondents. Compared to baseline, this group was younger (55.5 years versus 56.1 years) and composed of fewer women (27.6% versus 33.1%) and fewer low socioeconomic position participants (14.6% versus 22.7%) ($p < 0.001$). From this population, calculation of cognitive decline, implying participation in cognitive tests at Phase 7, was possible for 4,659 participants (figure 1). Here again, missing data were similarly influenced by age, gender and socioeconomic position compared to data available for analysis on cognitive deficit (N=5,388).

In order to assess whether the smoking-cognition association is underestimated due to premature mortality among smokers, we examined the association between smoking status at Phase 1 and mortality during the 17.1 (standard deviation=2.3) years of follow-up till Phase 7 (table 1). “Current smokers” at Phase 1 had a higher risk of dying during follow-up compared to “never smokers” after adjustment for age, socioeconomic position and marital status among men (Hazard Ratio (HR), 2.00 (95% confidence interval (CI), 1.58-2.52)) and women (HR, 2.46 (1.80-3.37)). Ex-smokers at Phase 1 did not have a higher risk of death during the period of follow-up examined (HR, 1.09 (0.84-1.41) among men, HR, 1.23 (0.84-1.79) among women). Among

survivors at Phase 7 (N=9,625), we examined the association between smoking status at Phase 1 and non-participation in the cognitive tests at Phase 7. In analyses adjusted for age, socioeconomic position and marital status, “current smokers” at Phase 1 were more likely to be non-participants among men (Odds Ratio (OR), 1.32 (1.16-1.51)) and women (OR, 1.69 (1.41-2.02)). In order to examine the persistence of this association, we repeated the analysis with smoking history at Phase 5 and participation in cognitive tests at Phase 7 (N=7,221). Greater numbers of both male (OR, 1.47 (1.20-1.81)) and female smokers (OR, 1.81 (1.35-2.43)) did not undertake the cognitive tests. “Long-term ex-smokers” and “recent ex-smokers” at Phase 5 were not different from “never smokers”.

Characteristics of individuals included in the analyses on smoking and cognitive deficit at Phase 5 are shown in table 2. The test for trend shows that smoking status was associated with socioeconomic position, education, alcohol and fruit and vegetable consumption ($p < 0.0001$). Prevalence of CHD, stroke and diabetes was not associated with smoking history. Among the vascular risk factors, smoking history was associated only with cholesterol ($p < 0.0001$). Cognitive scores at Phase 5 as a function of health measures are presented in Table 3.

Smoking history and cognitive function at Phase 5

The fully-adjusted mixed-effects model showed that smoking history was associated with memory ($p=0.01$), reasoning ($p=0.0004$), vocabulary ($p<0.0001$), phonemic ($p<0.0001$), and semantic fluency ($p=0.0009$). Table 4 presents results of the logistic regression using binary cognitive outcomes; the sex-specific cut-offs used are also shown. In age- and sex-adjusted models, “current smokers” were more likely to have cognitive deficits on all tests: memory (OR, 1.54 (1.25-1.90)), AH4-I (OR, 1.53 (1.27-1.85)), Mill Hill (OR, 1.42 (1.18-1.70)), phonemic (OR, 1.32 (1.09-1.60)) and semantic fluency (OR, 1.30 (1.08-1.57)). In fully adjusted models, the association remained for memory (OR, 1.37 (1.10-1.73)). Compared to “never smokers”, the “long-term ex-smokers” were less likely to have deficits in memory (OR, 0.79 (0.65-0.96)), the Mill Hill (OR, 0.73 (0.60-0.87)), phonemic (OR, 0.73 (0.61-0.87)) and semantic fluency (OR, 0.75

(0.63-0.89)) in fully adjusted models. “Recent ex-smokers” also had a reduced risk of poor vocabulary score (OR, 0.65 (0.49-0.85)) and semantic fluency (OR, 0.72 (0.55-0.94)).

Among current smokers at phase 5, in fully adjusted models, there was no evidence of a dose-response association between pack-years of smoking and cognitive deficit (memory, $p=0.97$; AH4-I, $p=0.13$; Mill Hill, $p=0.33$; phonemic, $p=0.25$; semantic fluency, $p=0.97$).

Smoking history and cognitive decline between Phases 5 & 7

The interaction term between smoking history and time in the fully-adjusted mixed-effects model showed that smoking history was associated with cognitive decline in reasoning ($p=0.0004$), but not with memory ($p=0.64$), vocabulary ($p=0.68$), phonemic ($p=0.63$), and semantic fluency ($p=0.61$); detailed results shown in the Appendix. Further analysis on decline (table 5) uses the worst quintile of change, implying decrease greater than 1 point for memory and the Mill Hill, 7 points for the AH4-I and 3 points for the fluency measures. In fully adjusted models, both “current smokers” (OR, 1.40 (1.11-1.75)) and “recent ex-smokers” (OR, 1.38 (1.07-1.77)) were more likely to decline on the AH4-I. No other association was evident. Further adjustment for health behaviours at Phase 7 did not much change these results.

Among current smokers at Phase 5, in fully adjusted models, there was no dose-response association between pack-years of smoking and cognitive decline (memory, $p=0.22$; AH4-I, $p=0.88$; Mill Hill, $p=0.54$; phonemic, $p=0.30$; semantic fluency, $p=0.94$).

Post-hoc analysis

This analysis was aimed at the exploration of changes in other health behaviours along with change in smoking status (giving up smoking) over the follow-up period. Those who stopped smoking between Phases 1 and 5 (“recent ex-smokers”) had the smallest increase in consumption of alcohol between Phases 1 and 7 (0.82 g of alcohol per week) compared to the other groups (1.46 g among “never smokers”). In terms of healthy eating, the percentage of participants consuming at

least one fruit or vegetable per day increased more among “recent ex-smokers” than among “never smokers”. Figure 2 shows that “recent ex-smokers” were at the same level of fruit and vegetable consumption as “current smokers” at Phase 1 but by Phase 7 they had reached the same level as “long-term ex-smokers” and “never smokers”.

COMMENT

This study presents four key findings. First, smoking in middle is associated with memory deficit and decline in reasoning abilities. Second, “long-term ex-smokers” are less likely to have cognitive deficits in memory, vocabulary and in verbal fluency. Third, giving up smoking in midlife is accompanied by improvement in other health behaviours. Finally, our results based on a large prospective cohort study of middle-aged British civil servants suggest that the association between smoking and cognition, even in late midlife, could be underestimated due to higher risk of death and non-participation among smokers.

Public health messages on smoking over the past twenty years have led to changes in smoking behaviour²³⁻²⁵. Thus, estimation of the association between smoking and any health outcome needs to assess smoking behaviour over time, explore whether change in smoking status is also accompanied by other changes, and to examine possible underestimation of the association due to premature mortality or greater loss to follow-up among smokers. Our analyses show all three aspects outlined above to be important. Exploration of the association between smoking and dementia in the elderly is complicated by the fact that it can only be among those who have “survived” long enough to become demented^{2,3}. The alternative is to examine cognitive deficit and decline at earlier ages. Cognition in midlife is clinically relevant as research suggests that individuals with mild cognitive impairment progress to clinically diagnosed dementia at an accelerated rate⁶⁻⁸.

Comparison with others studies

Studies using global cognitive tests (the Mini Mental State Examination, etc.) have found smoking to be associated with cognitive impairment²⁶⁻²⁹ and decline³⁰. Smokers have also been reported to have poorer vocabulary³¹, psychomotor speed¹¹, visuospatial performance^{12, 32}, memory^{12, 31, 32} and reasoning²⁷. Our results suggest poorer performance on memory and reasoning. Thus, the current evidence does not allow conclusions to be drawn about the association between smoking and specific cognitive domains.

Few studies⁹⁻¹⁵ have examined the association between smoking and cognition in a middle-aged population and only two of them^{12, 15} reported analysis on cognitive decline in this age group. Smoking was found to be associated with decline in memory in one study¹² but no association was found in the other¹⁵. Our results suggest a greater risk of deficit but not of decline in memory among smokers. A recent study suggests that the effect of smoking on decline in memory is confined to those over 75 years of age³². Future studies need to replicate these analyses in order to estimate the age at which smoking related decline in memory become apparent. Our results also show a decline in reasoning abilities among both recent ex-smokers and current smokers.

One could expect survival bias due to premature death of smokers to be limited among middle-aged individuals. Few studies^{33, 34} have measured this bias or the bias introduced by greater loss to follow-up amongst smokers. In our study, smoking was associated with loss to follow-up, both through death and non-participation. “Current smokers” at Phase 1 were twice as likely to die during the follow-up and those who were current smokers at Phase 1 or at Phase 5 were less likely to participate in the cognitive tests. These effects, either due to death or non-participation, were not evident among ex-smokers and their results on the association between smoking and cognition are likely not to be biased. Thus, the risk of cognitive deficit and decline among “current smokers” in our analyses may have been under-estimated. It is possible that those who are missing, either due to death or non-participation, had higher risk of cognitive deficit³⁵.

Previous results on the association between smoking and cognition in ex-smokers are mixed. In the EURODEM study, ex and never smokers did not differ on cognitive impairment³⁰.

Others have found the risk of cognitive impairment to be lower among ex-smokers compared to never smokers, even though the differences were not significant^{26, 28}. Apart from a few studies^{12, 28, 29}, most have looked at ex-smoking status without distinguishing between “long-term” and “recent” ex-smokers^{11, 26, 27, 30, 31}. In the 1946 British Birth Cohort study¹², ‘long-term ex-smokers’ had better memory and a slower decline in memory compared to “never smokers”. In the Honolulu-Asia Aging Study²⁸, “long-term ex-smokers” did not have a lower risk of cognitive impairment than “never smokers” and “recent ex-smokers” had the same increased risk of impairment as “current smokers”. Our results show that “long-term ex-smokers” were consistently less likely to have cognitive deficits for Mill Hill and verbal fluency. Future studies need to separate out the long-term ex-smokers from the recent ex-smokers.

The association between smoking and cognition could be explained by the fact that smoking is a risk factor of atherosclerotic disease³⁶, which is itself related to higher risk of cognitive deficit^{37, 38}. However, we did not find a dose-response association between pack-years of smoking and cognitive deficit/decline. Some studies have also reported the lack of a dose-response association²⁶⁻²⁸ while others have found this effect to be inconsistent^{12, 30}. It is possible that the loss of the heavy smokers, through death and non-participation, biases the results using pack-years of smoking. In relation to results among ex-smokers, it has been suggested that some of the differences in cognitive performance between groups defined by their smoking habit may be the consequence of self-selection out of the smoking groups. Thus, smokers with higher cognitive function scores would be more likely to quit and become ex-smokers²⁷. This hypothesis is plausible. However, a competing hypothesis is that those who stop smoking also change other health behaviours and possibly other aspects of their life as well. In our population, those who stopped smoking in the ten years preceding cognitive testing improved their other health behaviours (consumption of alcohol, fruits and vegetables) considerably when compared to others.

Strengths

This study has several strengths. The detailed prospective assessment allowed a precise lifelong smoking history to be established and several confounders and explanatory variables were included in the analysis. We were able to examine changes in health behaviours longitudinally. Furthermore, the design of the Whitehall II study allowed us to get a handle on the underestimation of the association between smoking and cognition by evaluating the extent of missing data, related to death during follow-up and to non-participation.

Limits

First, although the sample covered a wide socioeconomic range, the data are from white-collar civil servants and cannot be assumed to represent general populations. Second, smoking habits were self-reported and may have been under-reported. Third, the requirement to write down answers for tests of verbal fluency may have led to a restriction in response range. Finally, it is important to note that change between two time points is not enough to examine intra-individual change and analyses on further waves of data are necessary.

In conclusion, our results show an association between smoking and risk of memory deficit and reasoning decline. These results may have been under-estimated because of premature death and lower participation among smokers. Stopping smoking in middle-age was associated with improvement in other health behaviours and little residual adverse effect of smoking on cognition. Public health messages on smoking should continue to target smokers at all ages.

Reference List

1. Almeida OP, Hulse GK, Lawrence D, Flicker L. Smoking as a risk factor for Alzheimer's disease: contrasting evidence from a systematic review of case-control and cohort studies. *Addiction* 2002 January;971.:15-28.
2. Brayne C. Smoking and the brain. *BMJ* 2000 April 22;3207242.:1087-8.
3. Kukull WA. The association between smoking and Alzheimer's disease: effects of study design and bias. *Biol Psychiatry* 2001 February 1;493.:194-9.
4. Anstey KJ, von SC, Salim A, O'Kearney R. Smoking as a risk factor for dementia and cognitive decline: a meta-analysis of prospective studies. *Am J Epidemiol* 2007 August 15;1664.:367-78.
5. Kivipelto M, Ngandu T, Laatikainen T, Winblad B, Soininen H, Tuomilehto J. Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study. *Lancet Neurol* 2006 September;59.:735-41.
6. Chertkow H. Mild cognitive impairment. *Curr Opin Neurol* 2002 August;154.:401-7.
7. Petersen RC, Doody R, Kurz A et al. Current concepts in mild cognitive impairment. *Arch Neurol* 2001 December;5812.:1985-92.
8. Morris JC, Storandt M, Miller JP et al. Mild cognitive impairment represents early-stage Alzheimer disease. *Arch Neurol* 2001 March;583.:397-405.
9. Cerhan JR, Folsom AR, Mortimer JA et al. Correlates of cognitive function in middle-aged adults. Atherosclerosis Risk in Communities ARIC. Study Investigators. *Gerontology* 1998;442.:95-105.
10. Jacobsen LK, Krystal JH, Mencl WE, Westerveld M, Frost SJ, Pugh KR. Effects of smoking and smoking abstinence on cognition in adolescent tobacco smokers. *Biol Psychiatry* 2005 January 1;571.:56-66.
11. Kalmijn S, van Boxtel MP, Verschuren MW, Jolles J, Launer LJ. Cigarette smoking and alcohol consumption in relation to cognitive performance in middle age. *Am J Epidemiol* 2002 November 15;15610.:936-44.
12. Richards M, Jarvis MJ, Thompson N, Wadsworth ME. Cigarette smoking and cognitive decline in midlife: evidence from a prospective birth cohort study. *Am J Public Health* 2003 June;936.:994-8.
13. Starr JM, Deary IJ, Fox HC, Whalley LJ. Smoking and cognitive change from age 11 to 66 years: a confirmatory investigation. *Addict Behav* 2007 January;321.:63-8.
14. Whalley LJ, Fox HC, Deary IJ, Starr JM. Childhood IQ, smoking, and cognitive change from age 11 to 64 years. *Addict Behav* 2005 January;301.:77-88.
15. Knopman D, Boland LL, Mosley T et al. Cardiovascular risk factors and cognitive decline in middle-aged adults. *Neurology* 2001 January 9;561.:42-8.

16. Marmot MG, Smith GD, Stansfeld S et al. Health inequalities among British civil servants: the Whitehall II study. *Lancet* 1991 June 8;3378754.:1387-93.
17. Bornaards CM, Twisk JW, Snel J, Van MW, Kemper HC. Is calculating pack-years retrospectively a valid method to estimate life-time tobacco smoking? A comparison between prospectively calculated pack-years and retrospectively calculated pack-years. *Addiction* 2001 November;9611.:1653-61.
18. Heim AW. *AH 4 group test of general Intelligence*. Windsor, UK: NFER-Nelson Publishing Company Ltd.; 1970.
19. Raven JC. *Guide to using the Mill Hill vocabulary test with progressive matrices*. London, UK: HK Lewis; 1965.
20. Borkowski JG, Benton AL, Spreen O. Word fluency and brain damage. *Neuropsychologica* 1967;5:135-40.
21. Singh-Manoux A, Hillsdon M, Brunner E, Marmot M. Effects of physical activity on cognitive functioning in middle age: evidence from the Whitehall II prospective cohort study. *Am J Public Health* 2005 December;9512.:2252-8.
22. Ferrie JE, Langenberg C, Shipley MJ, Marmot MG. Birth weight, components of height and coronary heart disease: evidence from the Whitehall II study. *Int J Epidemiol* 2006 December;356.:1532-42.
23. Lee DJ, Fleming LE, Arheart KL et al. Smoking Rate Trends in U.S. Occupational Groups: The 1987 to 2004 National Health Interview Survey. *J Occup Environ Med* 2007 January;491.:75-81.
24. O'Connor RJ, Giovino GA, Kozlowski LT et al. Changes in nicotine intake and cigarette use over time in two nationally representative cross-sectional samples of smokers. *Am J Epidemiol* 2006 October 15;1648.:750-9.
25. Cummings KM. Programs and policies to discourage the use of tobacco products. *Oncogene* 2002 October 21;2148.:7349-64.
26. Cervilla JA, Prince M, Mann A. Smoking, drinking, and incident cognitive impairment: a cohort community based study included in the Gospel Oak project. *J Neurol Neurosurg Psychiatry* 2000 May;685.:622-6.
27. Elwood PC, Gallacher JE, Hopkinson CA et al. Smoking, drinking, and other life style factors and cognitive function in men in the Caerphilly cohort. *J Epidemiol Community Health* 1999 January;531.:9-14.
28. Galanis DJ, Petrovitch H, Launer LJ, Harris TB, Foley DJ, White LR. Smoking history in middle age and subsequent cognitive performance in elderly Japanese-American men. The Honolulu-Asia Aging Study. *Am J Epidemiol* 1997 March 15;1456.:507-15.
29. Launer LJ, Feskens EJ, Kalmijn S, Kromhout D. Smoking, drinking, and thinking. The Zutphen Elderly Study. *Am J Epidemiol* 1996 February 1;1433.:219-27.
30. Ott A, Andersen K, Dewey ME et al. Effect of smoking on global cognitive function in nondemented elderly. *Neurology* 2004 March 23;626.:920-4.

31. Stewart MC, Deary IJ, Fowkes FG, Price JF. Relationship between lifetime smoking, smoking status at older age and human cognitive function. *Neuroepidemiology* 2006;262.:83-92.
32. Reitz C, Luchsinger J, Tang MX, Mayeux R. Effect of smoking and time on cognitive function in the elderly without dementia. *Neurology* 2005 September 27;656.:870-5.
33. Edelstein SL, Kritz-Silverstein D, Barrett-Connor E. Prospective association of smoking and alcohol use with cognitive function in an elderly cohort. *J Womens Health* 1998 December;710.:1271-81.
34. Wang HX, Fratiglioni L, Frisoni GB, Viitanen M, Winblad B. Smoking and the occurrence of Alzheimer's disease: cross-sectional and longitudinal data in a population-based study. *Am J Epidemiol* 1999 April 1;1497.:640-4.
35. Tyas SL, Salazar JC, Snowdon DA et al. Transitions to mild cognitive impairments, dementia, and death: findings from the nun study. *Am J Epidemiol* 2007 June 1;16511.:1231-8.
36. Bolego C, Poli A, Paoletti R. Smoking and gender. *Cardiovasc Res* 2002 February 15;533.:568-76.
37. Singh-Manoux A, Britton AR, Marmot M. Vascular disease and cognitive function: evidence from the Whitehall II Study. *J Am Geriatr Soc* 2003 October;5110.:1445-50.
38. Tatemichi TK, Desmond DW, Stern Y, Paik M, Sano M, Bagiella E. Cognitive impairment after stroke: frequency, patterns, and relationship to functional abilities. *J Neurol Neurosurg Psychiatry* 1994 February;572.:202-7.

Table 1. Association between smoking and mortality and non-participation (2002-2004).

Smoking status at Phase 1 (1985-1988)	S e x	Never smoker	Ex-smoker	Current smoker	
Association with mortality till Phase 7 †	M	1	1.09 (0.84-1.41)	2.00 (1.58-2.52)*	
	F	1	1.23 (0.84-1.79)	2.46 (1.80-3.37)*	
Association with non participation at Phase 7 cognitive tests ‡	M	1	1.06 (0.93-1.21)	1.32 (1.16-1.51)*	
	F	1	1.08 (0.90-1.29)	1.69 (1.41-2.02)*	
Smoking status at Phase 5 (1997-1999)		Never smoker	Long-term ex-smoker	Recent ex-smoker	Current smoker
Association with non participation at Phase 7 cognitive tests §	M	1	0.95 (0.79-1.15)	1.04 (0.80-1.35)	1.47 (1.20-1.81)*
	F	1	0.96 (0.74-1.25)	1.23 (0.83-1.82)	1.81 (1.35-2.43)*

* p<0.05

† N= 6,841 men, N=3,371 women.

‡ N= 6,449 men, N=3,176 women, excluding participants lost to follow-up at Phase 7 due to death.

§ N= 5,064 men, N=2,157 women, excluding participants lost to follow-up at Phase 7 due to death.

Table 2. Characteristics of the study population at Phase 5 (1997-1999).*

	Never smoker	Long-term ex-smoker	Recent ex-smoker	Current smoker	P trend
N (N, %)	2,543 (47.2)	1,519 (28.2)	511 (9.5)	815 (15.1)	
Age (M, SD)	55.2 (6.0)	56.1 (6.0)	56.2 (6.0)	55.0 (5.7)	0.24
Women (N, %)	826 (32.5)	387 (25.5)	97 (18.2)	177 (21.7)	<.0001
High SEP (N, %)	932 (36.7)	525 (34.6)	180 (35.2)	231 (28.3)	<.0001
University degree or higher (N, %)	901 (35.4)	434 (28.6)	132 (25.8)	171 (21.0)	<.0001
Married/cohabiting (N, %)	1,908 (75.0)	1,217 (80.1)	395 (77.3)	600 (73.6)	0.87
Alcohol units/ week (M, SD)	10.5 (11.9)	15.3 (14.5)	17.1 (15.8)	20.6 (22.1)	<.0001
Hours of physical activity/week (M, SD)	21.9 (15.1)	22.7 (15.0)	23.1 (16.0)	21.5 (15.8)	0.98
Consumption of fruits & vegetable [†] (N, %)	1,966 (77.3)	1,152 (75.8)	373 (73.0)	509 (62.5)	<.0001
CHD (N, %)	143 (5.6)	87 (5.7)	48 (9.4)	48 (5.9)	0.18
Stroke (N, %)	18 (0.7)	13 (0.9)	3 (0.6)	8 (1.0)	0.55
Diabetes (N, %)	60 (2.4)	41 (2.7)	14 (2.7)	12 (1.5)	0.30
SBP (mmHg) (M, SD)	121.9 (16.4)	123.6 (16.6)	124.1 (16.9)	122.0 (15.6)	0.24
DBP (mmHg) (M, SD)	77.2 (10.6)	77.8 (10.3)	78.4 (11.2)	76.8 (10.0)	0.91
Cholesterol (mmol/l) (M, SD)	5.8 (1.0)	6.0 (1.0)	5.9 (1.0)	6.0 (1.1)	<.0001

*Analysis restricted to those with complete data (N=3,901 men, 1,487 women).

[†] Denotes at least daily consumption of fruits and vegetables.

M: Mean, SD: Standard deviation, CHD Coronary heart disease, SBP Systolic Blood Pressure, DBP Diastolic Blood Pressure.

Table 3. Cognitive function (mean (standard deviation)) as a function of health measures at Phase 5.*

	Memory	AH4-I	Mill Hill	Phonemic fluency	Semantic fluency
Range	0-20	0-65	0-33	0-35	0-36
CHD					
No	7.0 (2.4)	47.3 (10.7)	25.2 (4.3)	17.0 (4.4)	16.6 (4.1)
Yes	6.4 (2.3)	44.4 (12.0)	24.4 (4.9)	16.1 (4.4)	15.4 (4.3)
Stroke					
No	6.9 (2.4)	47.1 (10.7)	25.2 (4.3)	17.0 (4.4)	16.5 (4.2)
Yes	6.6 (2.6)	43.8 (10.7)	25.1 (3.8)	14.5 (3.3)	14.9 (3.5)
Diabetes					
No	6.9 (2.4)	47.3 (10.7)	25.2 (4.3)	17.0 (4.4)	16.5 (4.1)
Yes	6.4 (2.3)	41.3 (13.1)	23.1 (5.6)	15.6 (4.6)	15.0 (4.3)
SBP (mmHg)					
<140	7.0 (2.4)	47.5 (10.5)	25.2 (4.2)	17.1 (4.4)	16.6 (4.1)
≥140	6.6 (2.3)	44.8 (11.9)	24.7 (4.8)	16.1 (4.3)	15.9 (4.2)
DBP (mmHg)					
<90	6.9 (2.4)	47.1 (10.7)	25.2 (4.3)	17.0 (4.4)	16.5 (4.2)
≥90	6.7 (2.3)	46.9 (11.4)	25.1 (4.5)	16.7 (4.2)	16.4 (4.1)
Cholesterol (mmol/l)					
<4.92 (<240 mg/dL)	7.0 (2.3)	47.4 (10.8)	25.3 (4.5)	17.1 (4.5)	16.8 (4.2)
≥4.92 (≥240 mg/dL)	6.9 (2.4)	47.1 (10.8)	25.1 (4.3)	16.9 (4.4)	16.5 (4.2)

*Analysis restricted to those with complete data (N=3,901 men, 1,487 women).

CHD Coronary heart disease, SBP Systolic Blood Pressure, DBP Diastolic Blood Pressure.

Table 4. Odds ratio of being in the worst quintile of cognitive function at Phase 5 as a function of smoking status (1997-1999), N=5,388.[†]

	Never smoker N=2,543	Long-term ex-smoker N=1,519	Recent ex-smoker N=511	Current smoker N=815
Memory (<5)				
Adjusted for age & sex	1	0.80 (0.66-0.97)*	1.17 (0.90-1.51)	1.54 (1.25-1.90)*
+ sociodemographics [‡]	1	0.77 (0.63-0.93)*	1.10 (0.85-1.44)	1.33 (1.07-1.65)*
+ behaviours [§] & health [#]	1	0.79 (0.65-0.96)*	1.12 (0.86-1.47)	1.37 (1.10-1.73)*
AH4-I (<42 in men; <31 in women)				
Adjusted for age & sex	1	0.96 (0.82-1.14)	0.94 (0.74-1.20)	1.53 (1.27-1.85)*
+ sociodemographics [‡]	1	0.87 (0.73-1.05)	0.81 (0.61-1.06)	1.11 (0.90-1.37)
+ behaviours [§] & health [#]	1	0.91 (0.76-1.10)	0.83 (0.63-1.10)	1.20 (0.96-1.49)
Mill Hill (<24 in men; <20 in women)				
Adjusted for age & sex	1	0.87 (0.74-1.02)	0.84 (0.66-1.08)	1.42 (1.18-1.70)*
+ sociodemographics [‡]	1	0.72 (0.60-0.86)*	0.67 (0.51-0.88)*	0.97 (0.79-1.19)
+ behaviours [§] & health [#]	1	0.73 (0.60-0.87)*	0.65 (0.49-0.85)*	0.92 (0.74-1.15)
Phonemic fluency (<14 in men; <13 in women)				
Adjusted for age & sex	1	0.76 (0.64-0.90)*	1.00 (0.79-1.27)	1.32 (1.09-1.60)*
+ sociodemographics [‡]	1	0.70 (0.59-0.84)*	0.91 (0.71-1.17)	1.04 (0.85-1.28)
+ behaviours [§] & health [#]	1	0.73 (0.61-0.87)*	0.95 (0.74-1.22)	1.10 (0.89-1.35)
Semantic fluency (<14 in men; <13 in women)				
Adjusted for age & sex	1	0.80 (0.65-1.05)	0.82 (0.65-1.05)	1.30 (1.08-1.57)*
+ sociodemographics [‡]	1	0.73 (0.61-0.87)*	0.72 (0.56-0.93)*	0.97 (0.80-1.19)
+ behaviours [§] & health [#]	1	0.75 (0.63-0.89)*	0.72 (0.55-0.94)*	0.98 (0.79-1.21)

[†] Analysis restricted to those with complete data. * p<0.05

[‡] Socio-demographic variables: socioeconomic position, education and marital status.

[§] Health behaviours: alcohol, fruit and vegetable consumption and hours of physical activity at Phase 5.

[#] Health variables: prevalence of CHD, stroke and diabetes at Phase 5 and systolic blood pressure, diastolic blood pressure and cholesterol measurements at Phase 5.

Table 5. Odds ratio of being in the worst quintile of change in cognitive function between Phase 5 (1997-1999) and Phase 7 (2002-2004), N=4,659.

	Never smoker N=2,218	Long-term ex-smoker N=1,338	Recent ex-smoker N=443	Current smoker N=660
Memory (<-1)				
Adjusted for age & sex [†]	1	0.91 (0.78-1.06)	0.95 (0.75-1.21)	1.01 (0.83-1.23)
+ sociodemographics [‡]	1	0.91 (0.78-1.07)	0.95 (0.75-1.21)	1.01 (0.83-1.23)
+ behaviours [§] & health [#]	1	0.91 (0.77-1.06)	0.96 (0.75-1.22)	0.99 (0.80-1.22)
AH4-I (<-7)				
Adjusted for age & sex [†]	1	0.98 (0.82-1.18)	1.41 (1.10-1.82)*	1.46 (1.18-1.81)*
+ sociodemographics [‡]	1	0.97 (0.81-1.16)	1.40 (1.09-1.80)*	1.45 (1.09-1.80)*
+ behaviours [§] & health [#]	1	0.96 (0.80-1.16)	1.38 (1.07-1.77)*	1.40 (1.11-1.75)*
Mill Hill (<-1)				
Adjusted for age & sex [†]	1	1.04 (0.88-1.23)	1.01 (0.78-1.30)	1.01 (0.81-1.25)
+ sociodemographics [‡]	1	1.00 (0.85-1.19)	0.97 (0.75-1.25)	0.93 (0.75-1.25)
+ behaviours [§] & health [#]	1	1.01 (0.85-1.20)	0.97 (0.75-1.26)	0.95 (0.75-1.19)
Phonemic fluency (<-3)				
Adjusted for age & sex [†]	1	1.00 (0.85-1.19)	1.01 (0.79-1.30)	0.97 (0.79-1.21)
+ sociodemographics [‡]	1	1.02 (0.86-1.20)	1.03 (0.80-1.32)	1.00 (0.81-1.24)
+ behaviours [§] & health [#]	1	1.00 (0.84-1.18)	1.01 (0.78-1.30)	0.97 (0.78-1.21)
Semantic fluency (<-3)				
Adjusted for age & sex [†]	1	1.05 (0.88-1.25)	0.94 (0.72-1.24)	1.08 (0.86-1.35)
+ sociodemographics [‡]	1	1.03 (0.86-1.23)	0.94 (0.72-1.24)	1.09 (0.87-1.37)
+ behaviours [§] & health [#]	1	1.02 (0.85-1.23)	0.94 (0.71-1.24)	1.09 (0.86-1.38)

* p<0.05


[†] Analysis restricted to those with complete data and adjusted for time interval between Phases 5 & 7.

[‡] Socio-demographic variables: socioeconomic position, education and marital status.

[§] Health behaviours: alcohol, fruit and vegetable consumption and hours of physical activity at Phase 5.

[#] Health variables: prevalence of CHD, stroke and diabetes at Phase 5 and systolic blood pressure, diastolic blood pressure and cholesterol measurements at Phase 5.

Figure 1. Flow chart, (1985-2004).




Legend:

* Number of deaths since Phase 1

† N with missing sociodemographic variables =154, N with missing behavioral variables =236, N with missing health variables =156

Figure 2. Participants (%) consuming at least one fruit or vegetable per day as a function of smoking history at Phase 5.



Legend:

